1. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2020) Authors: Cree, Bruce A C; Cutter, Gary; Wolinsky, Jerry S; Freedman, Mark S; Comi, Giancarlo; Giovannoni, Gavin; Hartung, Hans-Peter; Arnold, Douglas; Kuhle, Jens; Block, Valerie; Munschauer, Frederick E; Sedel, Frédéric; Lublin, Fred D; Reingold, Stephen; Duquette, Pierre; Derfuss, Tobias; Fazekas, Franz... Journal: Lancet neurology Issue: Volume 19:Issue 12(2020) Page Start: 988 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗